C. Mahan

发表

Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse

M. Holdsworth, M. Borrego, A. Spyropoulos, 2011, Thrombosis and Haemostasis.

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

J. Ansell, S. Vazquez, D. Garcia, 2016, Journal of Thrombosis and Thrombolysis.

Renaissance of Aspirin for the Primary and Secondary Prevention of Venous Thromboembolism

Allison E. Burnett, C. Mahan, Brandi N. Bowman, 2013, Current Emergency and Hospital Medicine Reports.

Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.

P. Dobesh, J. Fanikos, Allison E. Burnett, 2017, The American journal of medicine.

Improving prevention and treatment of venous thromboembolism: clinical trial results

A. Spyropoulos, C. Mahan, 2012, Journal of medical economics.

Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism.

P. Dobesh, J. Fanikos, Allison E. Burnett, 2017, The American journal of medicine.

Venous Thromboembolism Pharmacy Intervention Management Program With an Active, Multifaceted Approach Reduces Preventable Venous Thromboembolism and Increases Appropriate Prophylaxis

A. Amin, M. Hussein, A. Spyropoulos, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants

S. Kaatz, David G. Paje, A. Nakhle, 2017, Current Cardiology Reports.

Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing

A. Spyropoulos, M. Pini, C. Mahan, 2010, Internal and emergency medicine.

Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients

A. Spyropoulos, C. Mahan, 2013 .

Prevention of Venous Thromboembolism in Medical Patients

A. Spyropoulos, C. Mahan, 2011 .

Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives.

A. Spyropoulos, C. Mahan, 2009, The American journal of medicine.

Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment

C. Mahan, 2015, Journal of Thrombosis and Thrombolysis.

Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.

J. Stephenson, M. Fisher, R. Mills, 2013, Thrombosis research.

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

S. Kaatz, Joseph J Gibbs, C. Mahan, 2017, Journal of blood medicine.

Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies

L. Valerio, S. Konstantinides, J. Douxfils, 2020, Hämostaseologie.

Reply to “Key Points to Consider When Evaluating Andexxa for Formulary Addition”

C. Mahan, 2020, Neurocritical Care.

Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory

D. Garcia, M. Borrego, Allison E. Burnett, 2016, Journal of Thrombosis and Thrombolysis.

European Union-28: An annualised cost-of-illness model for venous thromboembolism

F. Piovella, A. Spyropoulos, Stefano Barco, 2015, Thrombosis and Haemostasis.

Thrombophilia Issue.

T. Marcy, L. Hornsby, Allison E. Burnett, 2014, Journal of pharmacy practice.

Cost-of-illness model for venous thromboembolism.

A. Spyropoulos, Stefano Barco, C. Mahan, 2016, Thrombosis research.

Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry

A. Cohen, G. Agnelli, G. Giannakoulas, 2022, Journal of the American Heart Association.

Performance of New Anticoagulants for Thromboprophylaxis in Patients Undergoing Hip and Knee Replacement Surgery

S. Kaatz, C. Mahan, 2012, Pharmacotherapy.

ASHP Guidelines: Minimum Standard for Pharmacies in Hospitals

W. E. Smith, Jody Jacobson Wedret, M. Gillette, 2019, Best Practices.

Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.

T. Villines, T. Milling, C. Baugh, 2019, Annals of emergency medicine.

Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction

S. Kaatz, C. Mahan, 2014, Stroke.

Extended thromboprophylaxis in the acutely ill medical patient after hospitalization – a paradigm shift in post-discharge thromboprophylaxis

A. Spyropoulos, Allison E. Burnett, C. Mahan, 2018, Hospital practice.

The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation

Allison E. Burnett, C. Mahan, Ross Downey, 2013, Expert opinion on pharmacotherapy.

Identifying, monitoring and reducing preventable major bleeds in the hospital setting

A. Spyropoulos, C. Mahan, Deborah Caraballo, 2013, Journal of Thrombosis and Thrombolysis.

Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates

M. Borrego, A. Spyropoulos, C. Mahan, 2012, Thrombosis and Haemostasis.

Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

M. Holdsworth, M. Borrego, A. Spyropoulos, 2011, Thrombosis and Haemostasis.

All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients

J. Stephenson, M. Fisher, R. Mills, 2015, Thrombosis and Haemostasis.

New antithrombotics: the impact on global health care.

J. Fanikos, C. Mahan, 2011, Thrombosis research.

ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients.

A. Spyropoulos, C. Mahan, 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR)

N. Heddle, R. Cook, A. Turpie, 2014, Thrombosis and Haemostasis.

Venous Thromboembolism Prevention: A Systematic Review of Methods to Improve Prophylaxis and Decrease Events in the Hospitalized Patient

Charles E Mahan, Alexander C Spyropoulos, A. Spyropoulos, 2010, Hospital practice.

Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals.

C. Mahan, 2012, Thrombosis research.

A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

C. Mahan, 2014, Journal of Thrombosis and Thrombolysis.

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism

C. Coleman, T. Bunz, J. Beyer-Westendorf, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization

W. Klaskala, J. Stephenson, M. Fisher, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.

P. Dobesh, J. Fanikos, Allison E. Burnett, 2017, The American journal of medicine.

Extended thromboprophylaxis in the acutely ill medical patient after hospitalization – a paradigm shift in post-discharge thromboprophylaxis

A. Spyropoulos, Allison E. Burnett, C. Mahan, 2018, Hospital practice.